LY2603618

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LY2603618, covering 2018-10-25 to 2019-03-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors [Phase 1]